Opinion
New weight loss drugs raise questions of access, costs
New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health risks posed by obesity. Yet the drugs are so expensive that insurers are often choosing between two bad options: restricting access or raising consumer costs.
Popular weight loss drugs like Ozempic might be able to help with substance abuse, according to new research on people ...
I've watched several people, including myself, go on weight loss adventures, whether through rigid diets, intense gym ...
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
Zmyra is known as the top over-the-counter alternative to Wegovy for weight loss. This natural supplement packs a punch with ...
His comments come after Health Secretary Wes Streeting wrote in an opinion piece for the Telegraph that “our widening ...
Not everybody loses the same amount of weight on medications such as Ozempic and Saxenda—treatment indication, dosage, and ...
Doctors have said access to the drug is a "postcode lottery" as Sky News analysis reveals just 800 people have been ...
If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback